teva glp-1 Generic Version of Victoza Now Available Teva Brings First GLP-1 Generic

The inflection point for this growth curve was in early 2022 for diabetes and in October 2022 for obesity. The 2028 Forecast The bubble chart illustrates net Rx medicines spending growth for leading therapeutic areas, expected to grow between 4 and 7%

Stay on track with personalised goals, protein targets & healthy habits.

In this randomized clinical trial ...

On the flipside, there are challenges: for example, concerns about cost to healthcare systems and equity of access for patients with the greatest unmet needs, or the possible impact on Medtech currently used by patients suffering from obesity related conditions for example knee replacements for overweight patients with eroded joints or CPAP machines for sleep apnoea, a complication of obesity